Biocryst Pharmaceuticals: gibt es Meinungen dazu?

jetzt sogar in NY etwas billiger....  

auf jeden Fall. Das Unternehmen selbst ist aber ok ebenso der Status des anti-fluralen Medikaments (erfolgreich abgeschlossene Phase II).

Im Ernstfall (starker Ausbreitung), gäbe es sicher eine massive Unterstützung (von FDA, Regierung und grossen Pharmas) und Beschleunigung zur Marktreife.

Die Aktie ist bereits stark gestiegen - aber immer noch sehr wenig im Vergleich zu 2006. und wie gesagt unterchiedlich ist nun zu 2006: man ist jetzt viel näher zur Marktreife.

SICHER SPEKULATIV, aber ich bin drinnen mit einer Zockposition  

bald vom Virus heimgesucht wird:

http://portal.gmx.net/de/themen/gesundheit/...5900080429281xvFFm.html  

KK2,85 VK 3,51

KK 2,20 VK 3,45  

und wieder rein bei 3,07 Euro in USA..super volumen, float extrem niedrig!  

das virus dürfte sich weiterverbreiten und hat schon jetzt nach wenigen Tagen deutlich mehr Menschen infiziert und getötet als alle Vögelinfluenza viren der letzten 10 Jahre zusammen.

hier bleibt man - bis sich entweder eine grosse Verbreitung des Virus entwickelt hat oder bis es den Anschein hat, dass man den Ausbruch (hoffentlich doch noch) unter Kontrolle bekommt.

rein raus ist hier mM der falsche Ansatz; der Wirkstoff des Unternehmens ist gut, die Ergebnisse der Phase II klinischen Prüfung ebenfalls.  

 

wenn man summasumarum drin bleibt, kann man doch rein/raus traden!
Bin auch gestern abend nochmal um 3 rein

geschmissen wird und dann nicht mehr reinkommt.  

und hab den kurs im Auge, das passiert nicht!

http://investor.shareholder.com/biocryst/...tail.cfm?ReleaseID=366984

Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections

BIRMINGHAM, Ala., Feb 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced that the full data set from an exploratory Phase 2 study of peramivir in patients hospitalized for influenza was presented by the study's Principal Investigator, Dr. Michael G. Ison, Assistant Professor, Divisions of Infectious Diseases and Organ Transplantation at Northwestern University Feinberg School of Medicine, during the XI International Symposium on Respiratory Viral Infections taking place in Bangkok, Thailand, February 19 through February 22, 2009. This exploratory Phase 2 trial compared the efficacy and safety of five days of therapy with either 200 mg intravenous (i.v.) peramivir per day, 400 mg i.v. peramivir per day or 75 mg oral oseltamivir twice-a-day, in patients who required hospitalization related to influenza.

The primary objective of the study was to evaluate time to clinical stability, which is a composite endpoint comprised of normalization of temperature, oxygen saturation, respiratory rate, systolic blood pressure and heart rate. This type of endpoint has previously been used in pneumonia studies, but not in influenza. Secondary objectives of the study included evaluation of viral shedding, mortality, clinical relapse and time to resumption of usual activities. The primary efficacy population was defined as patients with confirmed influenza.

As reported in October 2008, there were no statistically significant differences in any of the efficacy endpoints between the three treatment arms, and peramivir was generally safe and well-tolerated at these dose levels. Evaluation of time to clinical stability, the primary endpoint, showed a median of 23.7 hours for peramivir 200 mg, 37.0 hours for peramivir 400 mg and 28.1 hours for oseltamivir (p=0.306). This exploratory endpoint was driven by resolution of fever. Viral shedding (time weighted change from baseline in viral titer) was reduced by a median of -2.0 logs for peramivir 200 mg, -2.1 logs for peramivir 400 mg, and -1.9 logs for oseltamivir (p=0.908). There was no mortality in the primary efficacy population, and there were no clinical relapses. Patients were discharged from hospital after a median of 4.0 days for peramivir 200 mg, 3.8 days for peramivir 400 mg, and 4.0 days for oseltamivir (p=0.994). The median number of days required for resumption of usual activities was 8.8 days for peramivir 200 mg, 9.0 days for peramivir 400 mg, and 13.7 days for oseltamivir (p=0.276).

"We are encouraged by these data and are currently working with the U.S. Food and Drug Administration to determine the next steps for peramivir as a treatment for patients hospitalized with influenza," said Dr. William P. Sheridan, BioCryst's Chief Medical Officer. "There are currently no approved treatment options for the 200,000 patients hospitalized for influenza each year and we believe peramivir may be a potential new option for these patients."

"This study greatly enhances our knowledge of the clinical and virologic course of influenza in hospitalized patients who receive neuraminidase inhibitors," stated Dr. Ison. "Peramivir holds promise as a once-daily intravenous treatment that is safe and potentially effective for use in patients with acute influenza, including the elderly and patients with underlying cardiac or pulmonary disease."

The multicenter, randomized, double-blind, double-dummy, active-controlled, Phase 2 study enrolled 137 patients, who tested positive by rapid antigen test (RAT) for influenza and had one or more criteria for hospitalization, namely: age greater than or equal to 60 years, chronic lung disease, congestive heart failure, diabetes mellitus, low oxygen saturation, low blood pressure, or severity of illness requiring supportive care. Of the 137 patients randomized, 122 age 19 to 101 years had influenza confirmed by polymerase chain reaction (PCR) testing and were included in the intent-to-treat infected (ITTI) patient population; 41 patients received oseltamivir 75 mg orally twice-daily, 41 patients received 200 mg i.v. peramivir once-daily and 40 patients received 400 mg i.v. peramivir once-daily. The study was conducted in the United States, Canada, Hong Kong, Singapore, Australia, New Zealand, and South Africa, in 2007 and 2008.

About Peramivir

Peramivir is an antiviral agent that inhibits the interactions of influenza neuraminidase, an enzyme which is critical to the spread of influenza within a host. In laboratory tests, peramivir has shown activity against viral strains that are resistant to currently available treatments and has been safely administered to healthy subjects at high dose levels. Peramivir is currently being studied in hospitalized and outpatient influenza, utilizing either an intramuscular or intravenous formulation. A Phase 2 trial in outpatient influenza is currently ongoing, the Phase 2 trial in hospitalized influenza was completed in 2008, and BioCryst's partner, Shionogi & Co., Ltd. has a pivotal Phase 3 program of peramivir in outpatient influenza underway.

About BioCryst

BioCryst is an integrated biopharmaceutical company utilizing crystallography and structure-based drug design to develop a deep pipeline of novel therapeutics targeting major illnesses. BioCryst is currently advancing investigational new drugs discovered in-house in late-stage clinical trials for influenza and lymphoma. In addition, the Company has a pre-clinical portfolio of novel compounds, directed against infectious, cardiovascular, and autoimmune disease targets, to create long-term sustainable value. The Company's strategic alliances with the U.S. Department of Health and Human Services, Shionogi & Co., Ltd., Green Cross Corporation and Mundipharma International Holdings Ltd. validate its scientific foundation and the utility of its product candidates. For more information, please visit the Company's Web site at www.biocryst.com .

Forward-looking statements

This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that our belief that many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular injection may not be correct, that HHS and the Food & Drug Administration (FDA) may not agree with our analysis, that HHS may further condition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future preclinical and clinical development may not have positive results, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not be able to retain its current pharmaceutical and biotechnology partners for further development of its product candidates or it may not reach favorable agreements with potential pharmaceutical and biotechnology partners for further development of its product candidates, that our projected burn rate may not be consistent with our expectations, that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, most recent Registration Statement on Form S-3 (filed November 28, 2008), Quarterly Reports on Form 10-Q, current reports on Form 8-K which identify important factors that could cause the actual results to differ materially from those contained in the projections or forward-looking statements.

BCRXW

SOURCE BioCryst Pharmaceuticals

@ Pichel, dann  ok (kann ich leider nicht), aber ich kann dir sagen: relax, die Seuche geht weiter und Biocrystal ist einer der ganz wenigen (kleinen) ernstzunehmenden Player.

@ alle anderen: ist dennoch sehr spekulativ !  

wenn du gerne möchten tust
vielleicht die

SINOVAC   - US - SVA



LABOPHARM  - US - DDSS



odda wenns richtich hot sein soll


ANADYS  - US - ANDS



odda wenn de ma die fronten wechseln willst


KODIAK  - US - KOG



anguggen
sind werte -welche bei ariva noch nich - odda kaum beachtung finden
unter us- trading-gesichtspunkten müssen die dat ooch nich

schönen tach noch und Gr.Gr.  

wenn ich mir deine lezten Plazierungen in den Jahresbörsenspiele so anschaue

http://tinyurl.com/cy6msm  

Released: 10/8/2007

Shares of BioCryst Pharmaceuticals soared on positive results from a study for the company's new lymphoma treatment.
BioCryst plans to present details from the study at the annual meeting of the American Society of Clinical Oncology, which will be held from May 29 to June 2 in Orlando, Fla.  

kommt erst langsam dann schneller (ab Herbst) auf die USA und Europa zu.  

als Folge der (erwarteten) starken Ausbreitung in den letzten Wochen auf mehreren Kontinenten. Es geht nun in die "exponentielle Phase" (die Kurve an Neuerkrankungen steigt stark an).

siehe mehr Info http://www.orf.at/090611-39252/index.html

Spätest im Herbst, werden auch einige Arivaner daran erkranken, mal sehen wer der erste hier sein wird. Erkrankung dürfte aber nicht stärker sein als eine "normale Grippe" sein, aber die ZAHL der Erkrankten und Toten dürfte deutlich ausfallen, weil es - im Unterschied zur "normalen Grippe" (mit der doch ein gewisser Anteil der Bevölkerung jedes Jahr Kontakt hat) - in der Bevölkerung keine nenneswerte Immunität besteht. Eine Belastung für die Gesundheitsbudgets dürfte sich in jedem Fall daraus ergeben.

Man muss hoffen, dass der (unwahrscheinliche aber mögliche) worst case ausbleibt und das Virus sich mit anderen Influenzaviren (zB den immer noch in Vogelpopulationen verbreiteten tödlichen Vogelgrippeviren) zu einem tödlicheren und zugleich kontagiösen Virus verändert. Wahrscheinlicher ist, dass sich das Virus in seinem globalen Seuchenzug über die nächsten 1-2 Jahre abschwächt und dann (fast) verschwindet bzw. irgendwann in späteren Jahren verändert wiederkommt.  

http://www.naturalnews.com/026503_pandemic_swine_flu_bioterrorism.html